BioSpace News Archive

ALR Technologies SG Ltd., the diabetes management company, announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM.

New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has approved

PolarityTE, Inc. announced that it signed a non-binding letter of intent with Michael Brauser for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash.

AcelRx Pharmaceuticals, Inc. announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 748,744 shares of its common stock, pre-funded warrants exercisable for an aggregate of 2,632,898 shares of common stock and common warrants exercisable for an aggregate of 4,227,052 shares of common stock.

AEON Biopharma, Inc. and Priveterra Acquisition Corp. announced the filing of Form S-4 Registration Statement with the U.S. Securities and Exchange Commission regarding the recently announced business combination between the two companies.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced that they have entered into a Research Collaboration and License Agreement with US-based Eli Lilly and Company focused on the discovery and development of novel peptide drug conjugates.

Janux Therapeutics, Inc. announced that the Company has submitted the investigational new drug application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.

Deka Biosciences, Inc., a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration on December 23, 2022.

AB Science SA announces that masitinib has been granted orphan drug status by the Swiss Agency for Therapeutic Products for the treatment of patients with amyotrophic lateral sclerosis.

Adaptive Biotechnologies Corporation announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.